Biotech Raptor (RPTP) plunged in early trading Monday after its drug candidate failed a trial in pediatric fatty liver disease. Raptor said its phase two trial of its candidate RP103 in nonalcoholic steatohepatitis (NASH) failed to meet its endpoint of a two-point improvement in a fatty-liver-disease scoring system, and no worsening of fibrosis, or scarring of the liver. “We’re disappointed with this outcome, given the paucity of treatment for
Rare-disease specialist Raptor Pharmaceuticals (RPTP) was up Friday, after it announced a buyout late Thursday that brings it into the field of cystic fibrosis. Raptor Pharmaceuticals inked a deal with privately held Tripex Pharmaceuticals to acquire Quinsair, an inhaled drug that helps manage chronic pulmonary infections that are common in CF patients. The drug has been approved in the European Union and Canada, though it hasn’t yet been
Rare-disease specialist Raptor Pharmaceutical (RPTP) was up 7% in early trading Thursday after Leerink lifted its price target on hopes for upcoming drug data. Analyst Joseph Schwartz affirmed his outperform rating and lifted his target to 20 from 15, citing a data readout in the third quarter on a clinical trial of Huntington’s disease drug RP103. Schwartz assigned a 60% probability of the drug ultimately getting to market, though he split the